Scarica l'app Stockscreener
4.86
6.81%
0.31
Pre-mercato:
4.78
-0.08
-1.65%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RXRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.55
Aprire:
$4.555
Volume 24 ore:
32.80M
Relative Volume:
0.83
Capitalizzazione di mercato:
$2.53B
Reddito:
$64.60M
Utile/perdita netta:
$-377.75M
Rapporto P/E:
-3.1355
EPS:
-1.55
Flusso di cassa netto:
$-335.64M
1 W Prestazione:
+18.83%
1M Prestazione:
+3.18%
6M Prestazione:
-1.42%
1 anno Prestazione:
-35.11%
Intervallo 1D:
$4.5441
$5.00
Intervallo di 1 settimana:
$4.12
$5.00
Portata 52W:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Nome
Recursion Pharmaceuticals Inc
Settore
Industria
Telefono
(385) 269-0203
Indirizzo
41S RIO GRANDE STREET, SALT LAKE CITY
Confronta RXRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.86 | 2.37B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Iniziato | Needham | Buy |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-04 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Iniziato | Berenberg | Buy |
| 2021-05-11 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Iniziato | JP Morgan | Neutral |
| 2021-05-11 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Recursion Pharmaceuticals Inc Borsa (RXRX) Ultime notizie
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates - Finviz
Recursion pharma director Gibson sells $170k in shares By Investing.com - Investing.com India
Recursion’s Stock Surge: An Opportunity? - StocksToTrade
Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates - Insider Monkey
RXRX Stock’s Impressive Surge: A Closer Look - timothysykes.com
Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus - simplywall.st
Recursion Pharmaceuticals Inc Stock Analysis and ForecastLow Risk Investment Ideas & AI-Based Insights for Consistent Profits - earlytimes.in
Recursion Pharmaceuticals, Inc. (RXRX) Investor Outlook: Uncovering a 60% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - AOL.com
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance Singapore
Is Recursion Pharmaceuticals (RXRX) Mispriced After Volatile Share Performance And Ongoing Tech Partnerships - simplywall.st
Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC - simplywall.st
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Insider Monkey
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Yahoo Finance
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares - MarketBeat
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares By Investing.com - Investing.com UK
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares - Investing.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares - MarketBeat
Recursion Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
RXRX Stock Plummet: Here’s What’s Happening - timothysykes.com
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP - Insider Monkey
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
10 AI Stocks Under $20 to Buy Now - Insider Monkey
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform - Finviz
Cathie Wood is doubling down on Recursion Pharmaceuticals stock. Should you buy RXRX here? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
Growth or Bubble? Decoding Recursion Pharmaceuticals’ Stock Surge - timothysykes.com
3 Small AI Plays to Buy for 2026 - Sahm
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data? - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition - ts2.tech
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
Recursion Pharmaceuticals Inc Azioni (RXRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):